The 43 references in paper D. Blinov V., U. Zimovina V., T. Ushakova I., Д. Блинов В., У. Зимовина В., Т. Ушакова И. (2015) “ФАРМАКОЭПИДЕМИОЛОГИЧЕСКАЯ ОЦЕНКА ГЕПАТОТРОПНОЙ ТЕРАПИИ В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ // PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE” / spz:neicon:pharmacoeconomics:y:2015:i:1:p:31-38

1
Belyakova N.M., Tetova V.B., Aleshkovich T.V. Infektsionnye Bolezni. 2006; 4 (1): 14-16.
(check this in PDF content)
2
Bueverov A.O., Bogomolov P.O. Klin. perspektivy gastroenterol. 2009; 1: 3-9.
(check this in PDF content)
3
Butorova L.I. Nonalcoholic fatty liver disease as a manifestation of the metabolic syndrome: epidemiology, pathogenesis, clinical manifestations, principles of diagnosis, current treatment options [Nealkogol'naya zhirovaya bolezn' pecheni kak proyavlenie metabolicheskogo sindroma: epidemiologiya, patogenez, osobennosti klinicheskogo proyavleniya, printsipy diagnostiki, sovremennye vozmozhnosti lecheniya]. Moscow. 2012. 52 s.
(check this in PDF content)
4
Vasilenko I.A., Dolgova G.V., Sorokoumova G.M., Khairetdinova M.N., Pomerantseva T.Ya. RMZh. 2010; 18 (6): 352-355.
(check this in PDF content)
5
Gundermann K.-I. Ross. Med. Vesti. 2009; 2: 1-7.
(check this in PDF content)
6
Gurevich K.G. Klinicheskaya farmakokinetika. 2004; 1: 52-57.
(check this in PDF content)
7
Drapkina O.M., Ivashkin V.T. RZhGGK. 2014; 4: 32-38.
(check this in PDF content)
8
Ivashkin V.T. The study DIREG 2. epidemiological studies on the prevalence of nonalcoholic fatty liver disease and identification of risk factors for the disease among patients outpatient practice. XX Russian Congress "Hepatology today." March 29, 2015 [Issledovanie DIREG 2. Epidemiologicheskoe issledovanie po izucheniyu rasprostranennosti nealkogol'noi zhirovoi bolezni pecheni i opredelenie faktorov riska razvitiya zabolevaniya sredi patsientov ambulatorno-poliklinicheskoi praktiki. XX Rossiiskii kongress «Gepatologiya segodnya». 29 marta 2015 g].
(check this in PDF content)
9
Isakov V.A. Eksperimental'naya i klinicheskaya gastroenterologiya. 2007; 2: 3-8.
(check this in PDF content)
10
Lipatova L.V. Epilepsiya i paroksizmal'nye sostoyaniya/Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
(check this in PDF content)
11
Makarov I.O., Borovkova E.I., Kazakov R.D. Akusherstvo, ginekologiya i reproduktsiya/Obstetrics, gynecology and reproduction. 2012; 4: 18-21.
(check this in PDF content)
12
Makarov I.O., Pavlov Ch.S., Shemanaeva T.V., Voevodin S.M., Muravei A.Yu. Akusherstvo, ginekologiya i reproduktsiya/Obstetrics, gynecology and reproduction. 2013; 1: 22-25.
(check this in PDF content)
13
Odinak M.M., Bazilevich S.N., Dyskin D.E., Prokudin M.Yu. Epilepsiya i paroksizmal'nye sostoyaniya/Epilepsy and paroxysmal conditions. 2010; 3: 45-50.
(check this in PDF content)
14
Polivanov V.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya/PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.
(check this in PDF content)
15
Polunina T.E. Gastroenterologiya. 2011; 5: 12-18.
(check this in PDF content)
16
Sas E.I., Blinov D.V., Zimovina U.V. Klinicheskie perspektivy gastroenterologii, gepatologii. 2015; 1: 9-17.
(check this in PDF content)
17
Smirnova O.M. Lechashchii Vrach. 2011; 3.
(check this in PDF content)
18
Essentiale Forte N. Instruction for for medical use [Essentsiale Forte N. Instruktsiya po meditsinskomu primeneniyu].
(check this in PDF content)
19
Yushchuk N.D., Martynov Yu.V., Znoiko O.O., Klimova E.A., Karetkina G.N., Maksimov S.L., Ivanova L.M., Mazus A.I., Golokhvastova E.L., Ol'shanskii A.Ya. Antiviral therapy of chronic viral hepatitis B and C in HIV-infected patients. Methodical letter. First Moscow State Medical Sechenov University [Protivovirusnaya terapiya khronicheskikh virusnykh gepatitov V i S u VICh-infitsirovannykh patsientov. Metodicheskoe pis'mo. MGMSU]. Moscow.
(check this in PDF content)
20
6. 20. Arvind N., Savaikar P., Rajkumar J. Therapy for NAFLD. A comparative study of essential phospholipids vs ursodeoxycholic acid. Indian J Clin Pract. 2006; 16: 21-24.
(check this in PDF content)
21
Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.-C., Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. The European Association for the Study of the Liver. EASL. 2013.
(check this in PDF content)
22
Cairella M., Callisto F., Godi R., Marchini G. Polyunsaturated phosphatidylcholine combined with vitamin B complex in the treatment of patients with disorders of the hepatobiliary function caused by unbalanced nutrition. 1998; 131: 237-246.
(check this in PDF content)
23
Chalasani N. et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592-1609.
(check this in PDF content)
24
Du Q. Treatment of 52 cases with hepatic dysfunctional fatty liver with Essentiale®. Chin J Gastro Hepa. 2004; 13: 21-24.
(check this in PDF content)
25
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. Journal of Hepatology. 2012; 57: 399-420.
(check this in PDF content)
26
EASL Recommendations on Treatment of Hepatitis C. 2014.
(check this in PDF content)
27
Fan J.G., Jia J.D., Li Y.M., Wang B.Y., Lu L.G., Shi J.P., et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis. 2011; 12: 38-44.
(check this in PDF content)
28
Gonciarz Z., Besser P., Lelek E., Gundermann K.J., Johannes K.J. Randomized placebo-controlled double-blind trial on “essential” phospholipids in the treatment of fatty liver associated with diabetes. Med. Chir. Digest. 1988; 17: 61-85.
(check this in PDF content)
29
Gundermann K.J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63: 643-659.
(check this in PDF content)
30
Ilis V., Begic-Janev A. Therapy of HBsAg-positive chronic active hepatitis. The efficacy of ‘essential” phospholipids. Me Welt. 1991; 42: 523-525.
(check this in PDF content)
31
La Brecque et al., World Gastroenterology Organisation Global Guidelines. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. J Clin Gastroenterol. 2014; 48 (6): 467-473.
(check this in PDF content)
32
Liang H. Discussion of treatment of fatty liver using polyene phosphatidylcholine capsules. Chinese Med Fact Mine. 2006; 19: 43.
(check this in PDF content)
33
Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202-19.
(check this in PDF content)
34
Niederau C., Strohmeyer G., Heintges T., Peter K., Gopfert E. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998; 45: 797-804.
(check this in PDF content)
35
Pacana T., Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease. Clin Liver Dis. 2012; 16: 599-613.
(check this in PDF content)
36
Panos M., Polson R., Johnson R., Portmann B., Williams R. polyunsaturated phosphatidylcholine for acute alcoholic hepatitis: a double-blind, randomized, placebo-controlled trial. Eur J Gastroenterol Hepatol.1990; 2: 351-355.
(check this in PDF content)
37
Sas E., Grinevich V., Kravchuk O., Efimov O. Polyunsaturated phosphatidylcholine reduces insulin resistance and hepatic fibrosis in patients with alcoholic liver disease. Results of randomized blinded prospective clinical study. Journal of Hepatology. 2011; 54: 207.
(check this in PDF content)
38
Schuller P.A., Gonzalez S.M.F. Controlled study with polyunsaturated phosphatidylcholine versus placebo in alcoholic fatty steatosis. Die Medizinische Welt. 1985; 36: 517-521.
(check this in PDF content)
39
Un C., Zheng X., Tan Z., Cui F., Zhang R., Zhang H. Clinical observation on polyene phosphatidylcholine and metformin in th treatment of type-2 diabetes and non-alcoholic fatty liver disease. Clin Focus. 2008; 23.
(check this in PDF content)
40
Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61 (4): 344-349.
(check this in PDF content)
41
Xu B., Ren C., Long B. Clinical Observation of 24 cases of Essentiale® Treating Alcoholic Fatty Liver. Sichuan Medical Journal. 2007; 28: 1116-1117.
(check this in PDF content)
42
Yin D., Kong L. Observation for curative effect of Essentiale® in treatment of fatty liver caused by diabetes mellitus. Med J Q. 2000;15: 277-278
(check this in PDF content)
43
Zhang X. Gong D., Wu S., Chen Q. Аndomized, controlled, double-blind, clinical trial of compound polyene phosphaticholine in treating chronic active hepatitis B. Chinese J Pharmacoepidemiol. 1995; 1. Сведения об авторах:
(check this in PDF content)